Inulin Gut Microbiome Randomized Trial: What the Evidence Says

Quick Answer

Inulin Gut Microbiome Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Synbiotics were found to be more effective than the administration of probiotics alone. [Schöttker Ben (2026); evidence level 2]
• Current literature provides no evidence of an increased risk of complications with probiotics supplementation in humans. [Schöttker Ben (2026); evidence level 2]
• In addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States. [Kozák Márk (2026); evidence level 3]
• Clinically, migraine is characterized by recurrent attacks of moderate-to-severe headache lasting 4-72 h, typically unilateral and pulsating, aggravated by routine physical activity, and frequently accompanied by photophobia and phonophobia; in a substantial subset of patients, attacks are associated with reversible focal neurological symptoms called aura. [Kozák Márk (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For inulin gut microbiome randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Schöttker Ben (2026). Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery. DOI: 10.1186/s12885-026-15903-9. PMCID: PMC13064029. PMID: 41882573. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13064029/
• Kozák Márk (2026). Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics. DOI: 10.3390/nu18050720. PMCID: PMC12986976. PMID: 41829891. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12986976/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.